Advancements in Personalized Cellular Immunotherapy
A Comprehensive Guide to Cancer Treatment
- 1st Edition - August 1, 2026
- Latest edition
- Editors: Arun Kumar Singh, Murali M. Yallapu, Ciniraj Raveendran, Pranav Kumar Prabhakar
- Language: English
Advancements in Personalized Cellular Immunotherapy: A Comprehensive Guide to Cancer Treatment is an authoritative guide that delves into the foundational principles, recent advanc… Read more
Advancements in Personalized Cellular Immunotherapy: A Comprehensive Guide to Cancer Treatment is an authoritative guide that delves into the foundational principles, recent advancements, and clinical applications of this innovative treatment approach, aiming to bridge the gap between research and clinical practice. It offers a thorough analysis of the mechanisms of action, therapeutic efficacy, and safety profiles of various cellular immunotherapy modalities, enabling clinicians to make well-informed treatment decisions and optimize patient outcomes. The book promotes interdisciplinary collaboration by bringing together experts from oncology, immunology, molecular biology, and translational medicine. Through detailed case studies, clinical guidelines, and practical insights, it provides healthcare professionals with the knowledge and tools needed to effectively incorporate cellular immunotherapy into standard oncology practice. Additionally, the book addresses key challenges and future directions in the field, such as strategies to enhance treatment efficacy, overcome resistance mechanisms, and broaden the accessibility of cellular immunotherapy to more patients. Advancements in Personalized Cellular Immunotherapy: A Comprehensive Guide to Cancer Treatment aims to educate and empower healthcare professionals, fostering continued innovation and collaboration to improve cancer care and patient outcomes.
- Offers an in-depth exploration of cellular immunotherapy, covering foundational principles, mechanisms of action, and clinical applications for both beginners and advanced professionals
- Illustrates the application of cellular immunotherapy, enhancing theoretical understanding and facilitating evidence-based clinical decision-making
- Discusses emerging trends, future directions, and challenges in cellular immunotherapy, including resistance mechanisms, treatment accessibility, and personalized medicine
Researchers working across the biosciences in fields of oncology, pharmacology and immunology
1. Introduction to Personalized Cellular Immunotherapy
2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy
3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy
4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues
5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives
6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors
7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies
8. The future of cancer immunotherapy: combining gene and cellular approaches
9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies
10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment
11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy
12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy
13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy
14. Combination therapy: a new strategy to manage cancer
15. Future perspective of cellular immunotherapy in cancer treatment
2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy
3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy
4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues
5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives
6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors
7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies
8. The future of cancer immunotherapy: combining gene and cellular approaches
9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies
10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment
11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy
12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy
13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy
14. Combination therapy: a new strategy to manage cancer
15. Future perspective of cellular immunotherapy in cancer treatment
- Edition: 1
- Latest edition
- Published: August 1, 2026
- Language: English
AS
Arun Kumar Singh
Arun Kumar Singh has completed M. Pharm (Pharmaceutics) from Galgotias University, Greater Noida, India. Mr. Singh joined as an assistant professor in the Department of Pharmacy, Vivekanand Global University Jaipur Rajasthan 303012. His area of interest is in the area of nano-formulation, blockchain, IoT, machine learning, cancer, artificial intelligence, big data, and neuroscience. He has authored one book with IOP publishing and has published 5 chapters in big data with River Publisher in Denmark. He has also published 20 review papers among which two are in Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. He has published 26 books with various publishers like IOP, Elsevier, CRC PRESS, and Wiley.
Affiliations and expertise
Assistant Professor, Department of Pharmacy, Vivekanand Global University Jaipur Rajasthan, IndiaMY
Murali M. Yallapu
Dr. Murali Yallapu is a tenured Associate Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology, and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews, with his work cited over 16,156 times. His primary research focuses on developing nanomaterials for enhanced therapeutic potential and cancer immunotherapy.
Affiliations and expertise
Director, RCMI Research Core Co-Director, CPRIT-ICRC Program Coordinator, CPRIT-TREC, School of Medicine, University of Texas Rio Grande Valley,CR
Ciniraj Raveendran
Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical Journal
Affiliations and expertise
Medical College Thiruvananthapuram, IndiaPP
Pranav Kumar Prabhakar
Dr. Pranav Kumar Prabhakar is currently working as a Professor in the Department of Biotechnology at Nagaland University, Kohima, Nagaland, India. He has been listed among the World’s Top 2% Scientists (as published by Stanford University, USA, in 2021, 2022, 2023, and 2024). He earned his PhD in Biotechnology from IIT Madras. His primary research interests include elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He also serves as an editorial board member and reviewer for several reputed national and international journals. Dr. Pranav has received various honors, including a travel grant to attend ATTD 2009 in Greece, sponsored by the Indian Institute of Technology Madras and the Council for Scientific and Industrial Research (CSIR), and approved by the Department of Science and Technology (DST). He has published over 115 research articles in journals, authored or edited 17 books, contributed more than 40 book chapters, and delivered 9 oral and poster presentations at scientific meetings.
Affiliations and expertise
Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland, India